News from the FDA/CDC

FDA: PrEP indication updated to include adolescents at risk of HIV infection


 

  • inconsistent or no condom use.
  • diagnosis of sexually transmitted infections.
  • exchange of sex for commodities (such as money, food, shelter, or drugs).
  • use of illicit drugs or alcohol dependence.
  • incarceration.
  • partner(s) of unknown HIV-1 status with any of the factors listed above.

Dosage and administration

2.1 Testing prior to initiation of Truvada for treatment of HIV-1 infection or for HIV-1 PrEP

Prior to or when initiating Truvada, test patients for hepatitis B virus infection [see Warnings and Precautions (5.1)].

Prior to initiation and during use of Truvada, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus

Pages

Recommended Reading

MicroRNAs flag liver damage in HIV-, HCV-infected persons
MDedge Internal Medicine
VIDEO: Women living with HIV have more myocardial steatosis, reduced diastolic function
MDedge Internal Medicine
MDedge Daily News: Can androgen therapy improve male frailty?
MDedge Internal Medicine
Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief
MDedge Internal Medicine
Comorbidity occurs earlier and more commonly with HIV infection
MDedge Internal Medicine
HIV infection linked to higher risk of non-melanoma skin cancer
MDedge Internal Medicine
Most HIV patients need treatment for acute HCV
MDedge Internal Medicine
New trial to assess HIV+/HIV+ kidney transplants
MDedge Internal Medicine
Emotional regulation training lowers risk of adolescents having sex
MDedge Internal Medicine
FDA approves epoetin alfa biosimilar to treat anemia
MDedge Internal Medicine